PT3377041T - Método para morcelação e/ou direcionamento de princípios farmaceuticamente ativos ao tecido sinovial - Google Patents

Método para morcelação e/ou direcionamento de princípios farmaceuticamente ativos ao tecido sinovial

Info

Publication number
PT3377041T
PT3377041T PT168227361T PT16822736T PT3377041T PT 3377041 T PT3377041 T PT 3377041T PT 168227361 T PT168227361 T PT 168227361T PT 16822736 T PT16822736 T PT 16822736T PT 3377041 T PT3377041 T PT 3377041T
Authority
PT
Portugal
Prior art keywords
morselizing
pharmaceutically active
active principles
synovial tissue
targeting
Prior art date
Application number
PT168227361T
Other languages
English (en)
Original Assignee
Maria Pereira Da Cruz Alves Garcia
Medincell S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maria Pereira Da Cruz Alves Garcia, Medincell S A filed Critical Maria Pereira Da Cruz Alves Garcia
Publication of PT3377041T publication Critical patent/PT3377041T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Mobile Radio Communication Systems (AREA)
PT168227361T 2015-11-16 2016-11-16 Método para morcelação e/ou direcionamento de princípios farmaceuticamente ativos ao tecido sinovial PT3377041T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562255778P 2015-11-16 2015-11-16

Publications (1)

Publication Number Publication Date
PT3377041T true PT3377041T (pt) 2023-12-15

Family

ID=57750301

Family Applications (1)

Application Number Title Priority Date Filing Date
PT168227361T PT3377041T (pt) 2015-11-16 2016-11-16 Método para morcelação e/ou direcionamento de princípios farmaceuticamente ativos ao tecido sinovial

Country Status (18)

Country Link
US (3) US20200155449A1 (pt)
EP (2) EP4374861A2 (pt)
JP (1) JP7036718B2 (pt)
KR (1) KR20180091016A (pt)
CN (1) CN108778245B (pt)
AU (1) AU2016355236C1 (pt)
CA (1) CA3004849A1 (pt)
DK (1) DK3377041T3 (pt)
ES (1) ES2964696T3 (pt)
FI (1) FI3377041T3 (pt)
HR (1) HRP20231453T1 (pt)
HU (1) HUE064329T2 (pt)
LT (1) LT3377041T (pt)
PL (1) PL3377041T3 (pt)
PT (1) PT3377041T (pt)
RS (1) RS64926B1 (pt)
SI (1) SI3377041T1 (pt)
WO (1) WO2017085561A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11801217B2 (en) * 2017-07-17 2023-10-31 Medincell S.A. Biodegradable block copolymer drug delivery composition
GB201900258D0 (en) * 2019-01-08 2019-02-27 Medincell Pharmaceutical composition
EP4014963A1 (en) * 2020-12-16 2022-06-22 Medincell Pharmaceutical composition
GB202104224D0 (en) 2021-03-25 2021-05-12 Medincell Pharmaceutical composition

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3377364A (en) 1957-09-23 1968-04-09 Upjohn Co 6-methyl-17alpha-hydroxyprogesterone, the lower fatty acid 17-acylates and methods for producing the same
US3043832A (en) 1961-02-27 1962-07-10 Ormonoterapia Richter Spa Preparation of 6alpha-methyl-17alpha-hydroxyprogesterone and 17alpha-esters thereof
ATE37983T1 (de) 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
GB8416234D0 (en) 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
US5071643A (en) 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
DE68916860T2 (de) 1988-05-23 1995-03-16 Procter & Gamble Aufsaugende Strukturen aus gemischten Zellstoffen.
US5632727A (en) 1988-10-03 1997-05-27 Atrix Laboratories, Inc. Biodegradable film dressing and method for its formation
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5221534A (en) 1989-04-26 1993-06-22 Pennzoil Products Company Health and beauty aid compositions
US5077049A (en) 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
USRE37950E1 (en) 1990-04-24 2002-12-31 Atrix Laboratories Biogradable in-situ forming implants and methods of producing the same
HU222501B1 (hu) 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
ATE288270T1 (de) 1993-11-19 2005-02-15 Janssen Pharmaceutica Nv Mikroverkapselte 1,2-benzazole
KR0148704B1 (ko) 1994-01-10 1998-08-17 김상응 생체분해성 약물전달용 고분자
WO1995027481A1 (en) 1994-04-08 1995-10-19 Atrix Laboratories, Inc. Liquid delivery compositions
WO1996021427A1 (en) 1995-01-09 1996-07-18 Atrix Laboratories, Inc. Liquid polymer delivery system
KR0180334B1 (ko) 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
FR2741628B1 (fr) 1995-11-29 1998-02-06 Centre Nat Rech Scient Nouveaux hydrogels a base de copolymeres trisequences et leur application notamment a la liberation progressive de principes actifs
JPH09208494A (ja) 1995-11-30 1997-08-12 Kanebo Ltd 微粒子製剤
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
IL118235A0 (en) 1996-05-13 1996-09-12 Univ Ben Gurion Composition and method for forming biodegradable implants in situ and uses of these implants
US5711958A (en) 1996-07-11 1998-01-27 Life Medical Sciences, Inc. Methods for reducing or eliminating post-surgical adhesion formation
US20020164374A1 (en) 1997-10-29 2002-11-07 John Jackson Polymeric systems for drug delivery and uses thereof
US6261583B1 (en) 1998-07-28 2001-07-17 Atrix Laboratories, Inc. Moldable solid delivery system
DE19849589C1 (de) 1998-10-27 2000-06-15 Glatt Process Technology Gmbh Fibrin-Gewebekleber-Formulierung und Verfahren zu dessen Herstellung
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
KR100416242B1 (ko) 1999-12-22 2004-01-31 주식회사 삼양사 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법
CA2401340A1 (en) 2000-02-28 2001-09-07 The University Of British Columbia Compositions and methods for the treatment of inflammatory disease using topoisomerase inhibitors
US7018645B1 (en) 2000-04-27 2006-03-28 Macromed, Inc. Mixtures of various triblock polyester polyethylene glycol copolymers having improved gel properties
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
WO2002012369A1 (fr) 2000-08-07 2002-02-14 Wako Pure Chemical Industries, Ltd. Polymere d'acide lactique et son procede de preparation
AU2002241631A1 (en) 2000-10-31 2002-06-18 Honeywell International, Inc. Improvement of flow characteristics of metal feedstock for injection molding
KR100446101B1 (ko) 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물
US20030105144A1 (en) * 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
AR035293A1 (es) 2001-08-23 2004-05-05 Novartis Ag Composicion oftalmica.
US6592899B2 (en) 2001-10-03 2003-07-15 Macromed Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
FR2832084B1 (fr) 2001-11-12 2004-05-14 Vai Clecim Procede et dispositif de stabilisation du defilement a grande vitesse d'un produit en bande
EP1504047B1 (en) 2002-05-03 2007-12-12 Janssen Pharmaceutica N.V. Polymeric microemulsions
US20030228366A1 (en) 2002-06-11 2003-12-11 Chung Shih Reconstitutable compositions of biodegradable block copolymers
US7649023B2 (en) 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
US7160551B2 (en) 2002-07-09 2007-01-09 The Board Of Trustees Of The University Of Illinois Injectable system for controlled drug delivery
AU2003287235A1 (en) * 2002-10-28 2004-05-25 Polymerix Corporation Therapeutic compositions
US7186789B2 (en) 2003-06-11 2007-03-06 Advanced Cardiovascular Systems, Inc. Bioabsorbable, biobeneficial polyester polymers for use in drug eluting stent coatings
NL1023720C2 (nl) 2003-06-23 2004-12-28 Univ Eindhoven Tech Werkwijze voor het wijzigen van de transporteigenschappen van een materiaal, werkwijze voor het vrijmaken van een werkstof uit een implantaat, evenals implantaat met werkstof.
US20050112170A1 (en) 2003-11-20 2005-05-26 Hossainy Syed F. Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same
US7262253B2 (en) 2003-12-02 2007-08-28 Labopharm, Inc. Process for the preparation of amphiphilic poly (N-vinyl-2-pyrrolidone) block copolymers
AU2006269927B2 (en) 2004-01-12 2013-05-16 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
WO2005070332A1 (en) 2004-01-12 2005-08-04 The Trustees Of The University Of Pennsylvania Long-term delivery formulations and methods of use thereof
AU2005210668A1 (en) * 2004-01-30 2005-08-18 Angiotech International Ag Compositions and methods for treating contracture
US20060034889A1 (en) 2004-08-16 2006-02-16 Macromed, Inc. Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof
US20090117177A1 (en) 2005-05-23 2009-05-07 Natalia Rapoport Echogenic microbubbles and microemulsions for ultrasound-enhanced nanoparticle-mediated delivery of agents
US7767710B2 (en) 2005-05-25 2010-08-03 Calosyn Pharma, Inc. Method for treating osteoarthritis
EP1909774A2 (en) 2005-08-04 2008-04-16 Angiotech International Ag Block copolymer compositions and uses thereof
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
CN103071209A (zh) 2005-11-17 2013-05-01 周吉尼克斯股份有限公司 用无针注射递送粘稠制剂
AR064286A1 (es) 2006-12-13 2009-03-25 Quiceno Gomez Alexandra Lorena Produccion de dispositivos oftalmicos basados en la polimerizacion por crecimiento escalonado fotoinducida
BRPI0811319A2 (pt) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
US20090004243A1 (en) 2007-06-29 2009-01-01 Pacetti Stephen D Biodegradable triblock copolymers for implantable devices
CL2008003305A1 (es) 2007-11-06 2009-06-05 M/S Panacea Biotec Ltd Composicion inyectable que comprende un agente activo seleccionado de un grupo definido; al menos un polimero bioerosionable, al menos un solvente no toxico y opcionalmente uno o mas excipientes; proceso de preparacion; uso para tratar enfermedades mentales o cancer.
EP2359880A3 (en) 2008-02-04 2011-09-21 Nilimedix Ltd. Drug delivery system with wireless monitor
US8846068B2 (en) 2008-04-18 2014-09-30 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising a local anesthetic
KR20190026056A (ko) 2008-04-21 2019-03-12 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
JP6363320B2 (ja) 2008-06-16 2018-07-25 ファイザー・インク 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法
US20110224151A1 (en) 2008-11-21 2011-09-15 Samyang Corporation Polymeric Micelle Composition for Treatment of Resistant Cancer and Preparation Method of the Same
JP2010215562A (ja) 2009-03-17 2010-09-30 Kansai Univ 膨隆剤組成物および膨隆剤製造方法
CN101810580A (zh) 2010-05-09 2010-08-25 王丽燕 一种缬沙坦脂质体、其制备方法及包含它的药物组合物
GB2513267B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
SG10201508568VA (en) * 2010-12-29 2015-11-27 Medincell Biodegradable drug delivery compositions
EP2691078A1 (en) 2011-03-31 2014-02-05 Ingell Technologies Holding B.V. Biodegradable compositions suitable for controlled release
US8936784B2 (en) 2011-10-17 2015-01-20 Poly-Med, Inc. Absorbable in situ gel-forming system, method of making and use thereof
JP6134788B2 (ja) 2012-06-27 2017-05-24 メドインセルル 疎水性組成物のための生分解性薬物送達
WO2015110915A2 (en) 2014-01-27 2015-07-30 Medincell Retro-inverso analogs of spadin display increased antidepressant effects
US9732744B2 (en) 2015-04-22 2017-08-15 Sheng-Yi YEH Detachable ball inflation and deflation device
WO2017119928A1 (en) 2016-01-08 2017-07-13 Abon Pharmaceuticals, Llc Long acting injectable formulations
WO2018015915A1 (en) 2016-07-22 2018-01-25 Cadila Healthcare Limited A parenteral controlled release composition of an atypical antipsychotic agent
CN110740752B (zh) 2017-06-13 2023-11-17 不列颠哥伦比亚大学 用于药物递送的聚合物糊剂组合物

Also Published As

Publication number Publication date
JP2018537454A (ja) 2018-12-20
SI3377041T1 (sl) 2024-02-29
WO2017085561A1 (en) 2017-05-26
JP7036718B2 (ja) 2022-03-15
CN108778245A (zh) 2018-11-09
EP3377041B1 (en) 2023-10-25
HUE064329T2 (hu) 2024-03-28
LT3377041T (lt) 2023-12-27
FI3377041T3 (fi) 2023-11-30
CA3004849A1 (en) 2017-05-26
CN108778245B (zh) 2022-05-13
EP4374861A2 (en) 2024-05-29
AU2016355236B2 (en) 2021-12-23
US11865205B2 (en) 2024-01-09
PL3377041T3 (pl) 2024-03-11
AU2016355236A1 (en) 2018-05-31
HRP20231453T1 (hr) 2024-03-01
AU2016355236C1 (en) 2022-09-22
KR20180091016A (ko) 2018-08-14
US20200155449A1 (en) 2020-05-21
RS64926B1 (sr) 2023-12-29
EP3377041A1 (en) 2018-09-26
US20210322302A1 (en) 2021-10-21
US20240000703A1 (en) 2024-01-04
ES2964696T3 (es) 2024-04-09
DK3377041T3 (da) 2023-12-18

Similar Documents

Publication Publication Date Title
HUS2100006I1 (hu) Avapritinib és gyógyászatilag elfogadható sói
IL253712B (en) Mysterlein derivatives for coupling and healing
HUE052925T2 (hu) Amid származékok és azok gyógyászatilag elfogadott sói, elõállítási módszere és gyógyászati alkalmazása
PL3273942T3 (pl) Plaster mikroigłowy do dostarczania składnika aktywnego do skóry
IL247795A0 (en) tco couplings and methods for shipping medical materials
ZA201601146B (en) Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug
IL253549B (en) Antibody-urease conjugates for therapeutic purposes
HK1245639A1 (zh) 纖維化病治療劑
HK1247140A1 (zh) 用於藥物有效地呼吸同步遞送到肺部的方法和系統
SI3377041T1 (sl) Postopek delitve in/ali targetiranja farmacevtsko aktivnih učinkovin sinovialnemu tkivu
HK1247556A1 (zh) 難溶性藥物傳遞用的可溶性微針
WO2014155389A3 (en) Process for preparation of ticagrelor
EP3325096A4 (en) SYSTEM AND METHOD FOR DELIVERING A LIGHT DETERMINED TO A FABRIC
HK1253332A1 (zh) 消融組織的方法和系統
IL240710A0 (en) Administration of sdf-1 to treat ischemic tissue
GB201519919D0 (en) Pharmaceutically active compounds
GB201508787D0 (en) Pharmaceutically active compounds
GB201415384D0 (en) Caron dioxide plasma treatment